Treats multiple myeloma. Sold as Zenbexus. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Iberdomide Hydrochloride (sold as Zenbexus), first approved Aug 13, 2026, with 0 new uses approved and 0 published complete response letters.
| Program | Updated |
|---|---|
| Zenbexus REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled | Aug 13, 2026 |
| ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaMyeloma, Multiple Myeloma · Omar Nadeem, MD | Phase 1 | Recruiting | Jul 24, 2024 |
| Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple MyelomaSmoldering Plasma Cell Myeloma · Emory University | Phase 2 | Recruiting | Mar 1, 2021 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 13, 2026 | ZenbexusNDA 221075 · New molecular entity | Bristol Myers Squibb | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bristol Myers Squibb